BIOCON

Boosted by U.S. FDA Nod

Big win for

today! The company received a tentative U.S. FDA approval for its diabetes drug Sitagliptin. Could this mark the start of a major overseas breakthrough? #Biocon #Pharma #FDAApproval #IndiaPharma” Highlights: Biocon secured a tentative approval from the U.S. FDA for its diabetes treatment Sitagliptin. This approval could open doors to the U.S. generics market, adding strong revenue potential. Reinforces Biocon’s growing foothold in the global pharmaceutical space.